 | |
| Company type | Subsidiary |
|---|---|
| Nasdaq: CBST | |
| Industry | Pharmaceuticals (Biopharmaceuticals & Biotherapeutics) |
| Founded | 1992; 33 years ago (1992) |
| Defunct | 2015 (2015) |
| Headquarters | Lexington, Massachusetts |
Key people | Robert J. Perez (president &CEO) |
| Products | Product Pipeline |
| Revenue |  $926.4 millionUSD (2012) |
| Parent | Merck & Co. |
| Website | www.cubist.com |
Cubist Pharmaceuticals, Inc. was an Americanbiopharmaceutical company that targeted pathogens likeMRSA.
.[1] The company employed 638 people, mostly inLexington, Massachusetts.[2] On 8 December 2014,Merck & Co. acquired Cubist for $102 per share in cash ($8.4 billion).[3]
Cubist was founded in May 1992 by John K. Clarke,Paul R. Schimmel, Ph.D. and Barry M. Bloom, Ph.D, all of whom were also directors.[4]Cubist appeared on Fortune 2010’s List of fastest growing companies, and was named to the 2010 Deloitte Technology Fast 500.[5]
In 2011, the company acquired Adolor, maker of a drug for treatment ofconstipation.[6]
The company expected sales of its drug Cubicin to grow to more than 1 billion dollars per year.
In July 2013, Cubist Pharmaceuticals agreed to purchaseTrius Therapeutics andOptimer Pharmaceuticals for around $1.6 billion.[7]
In 2014, succeedingMichael Bonney as President, Robert J. Perez, was announced to take leadership on January 1, 2015.[8]
In January 2015 Cubist Pharmaceuticals became a wholly owned subsidiary of Merck & Co.
The company developed Cubicin (daptomycin) for injection, the first antibiotic in a class of anti-infectives calledlipopeptides. In 2011, Cubist settled a patent litigation withTeva Pharmaceutical Industries regarding Cubicin.[9]In April 2011 it reached a deal with Optimer Pharmaceuticals in which its class of bacterium-fighting drugs will be co marketed with Optimer's Fidaxomicin/Dificid (for $15 million per year).[10]
In 2011, its product pipeline focused on gram-negative bacterial infections,[11]Clostridioides difficile infection,[12] andrespiratory syncytial virus.[13]
Tedizolid was approved by the USFood and Drug Administration on June 20, 2014.[14][15]
42°25′25.2″N71°14′32.9″W / 42.423667°N 71.242472°W /42.423667; -71.242472
